99% Savings - Buy Just @1 Rs X
Ranolaz 500 Tablet is a prescription medicine that is available as a Tablet. It is primarily used for the treatment of Angina.
The right dosage of Ranolaz 500 Tablet depends on the age, gender, and medical history of the patient. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
While these are the most often observed Ranolaz 500 Tablet side effects, there are can be others also. These have been listed below. Normally, these side effects of Ranolaz 500 Tablet are not long lasting and go away when the treatment is finished. If, however, they worsen or do not go away, please speak with your physician.
Ranolaz 500 Tablet's effect during pregnancy is Severe and Severe while nursing. It is important to know if Ranolaz 500 Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Ranolaz 500 Tablet related warnings section.
Ranolaz 500 Tablet can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Ranolaz 500 Tablet in conditions like Liver Disease. Some other conditions that can be affected by Ranolaz 500 Tablet are listed in the contraindications section below.
Drug interactions for Ranolaz 500 Tablet have been reported in the medical literature. Refer to the list below for further details.
In addition to the above precautions for Ranolaz 500 Tablet, it is important to know that it is not safe while driving, and is not habit-forming.
Ranolaz 500 Tablet is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Ranolaz 500 Tablet safe for pregnant women?
Ranolaz has many dangerous side effects in pregnant women. If you are pregnant, do not consume Ranolaz without medical advice.
Is the use of Ranolaz 500 Tablet safe during breastfeeding?
Women who are breastfeeding may experience severe harmful effects after taking Ranolaz. It should only be taken after medical advice.
What is the effect of Ranolaz 500 Tablet on the Kidneys?
Ranolaz rarely harms the kidneys.
What is the effect of Ranolaz 500 Tablet on the Liver?
Ranolaz is rarely harmful for the liver.
What is the effect of Ranolaz 500 Tablet on the Heart?
Ranolaz is rarely harmful for the heart.
If you are suffering from any of the following diseases, you should not take Ranolaz 500 Tablet unless your doctor advises you to do so -
Is this Ranolaz 500 Tablet habit forming or addictive?
Forming a habit of Ranolaz 500 Tablet has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Ranolaz 500 Tablet. So it is best to avoid driving.
Is it safe?
Yes, but consume Ranolaz 500 Tablet only on doctor's advice.
Is it able to treat mental disorders?
No, Ranolaz 500 Tablet cannot treat any kind of mental disorder.
Interaction between Food and Ranolaz 500 Tablet
Eating certain foods may increase the time it takes Ranolaz 500 Tablet to have an effect. You should consult your doctor about it.
Interaction between Alcohol and Ranolaz 500 Tablet
No research has been done on this till date. Therefore, it is not known what the effect of taking Ranolaz 500 Tablet with alcohol will be.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Ranexa (ranolazine)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 554
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1084-1085